AASLD 2023 The Liver Meeting®

AASLD 2023 The Liver Meeting®
November 10-14, 2023
Boston, Massachusetts, USA

American Association for the Study of Liver Diseases, The Liver Meeting®.

Explore more information for Gilead Liver Diseases therapies
Results (15)

Risk Factors and Natural History of Hepatocellular carcinoma (HCC): Observations following successful sofosbuvir-based treatment in HCV patients with cirrhosis

No detectable resistance to bulevirtide monotherapy through 96 weeks treatment in patients with chronic hepatitis D

Improvement in noninvasive tests (LSM, FIB-4, and APRI) is seen through 96 weeks of bulevirtide monotherapy in CHD regardless of virologic response

Impact of Long-term Treatment With Continuous Tenofovir Alafenamide or After Switching From Tenofovir Disoproxil Fumarate on Hepatocellular Carcinoma Incidence in Patients With Chronic Hepatitis B

Results From an Integrated Analysis at Week 96: Continued Treatment of Early Virologic Non-responders or Partial Responders With Bulevirtide Monotherapy for Chronic Hepatitis Delta Leads to Improvement in Virologic and Biochemical Responses 

No resistance to tenofovir alafenamide (TAF) in adult, HBeAg-positive and HBeAg-negative participants with chronic hepatitis B infection treated with TAF for up to 8 years

Factors associated with a lack of viral suppression in chronic HBV (CHB) patients after 8 years of treatment with tenofovir alafenamide (TAF) or tenofovir disporoxil (TDF) followed by TAF treatment

Efficacy and Safety of Tenofovir Alafenamide (TAF) at 2 Years in Children and Adolescents With Chronic Hepatitis B (CHB)

No Detected Resistance to Tenofovir Alafenamide (TAF) Through 96 Weeks of Treatment in Children and Adolescents with Chronic Hepatitis B

Long-term safety and efficacy of sofosbuvir-based direct-acting antivirals in pediatric patients with hepatitis C virus

Patients with Chronic Hepatitis C could be treated with Sofosbuvir/Velpatasvir for 12 weeks by non-specialists: final analysis of HELIOS-3

Relationship Between ALT Normalization Rates and Different Virologic Response Criteria in Chronic HDV (CHD) Patients Treated with Bulevirtide (BLV) Monotherapy

Bone and Renal Safety of Tenofovir Alafenamide (TAF) at 8 Years in Chronic HBV (CHB) Patients with Underlying Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)

Baseline Characteristics of Hepatitis Delta Patients Enrolled Across Phase 2 and 3 Studies of Bulevirtide

Development of Antidrug Antibodies on Bulevirtide Monotherapy in Chronic Hepatitis Delta Does Not Impact Bulevirtide Efficacy, Safety, or Pharmacokinetics